Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood pressure Drug's safety checked in cortisol study

NCT ID NCT06336356

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether baxdrostat, an experimental drug for high blood pressure, affects the body's stress hormone cortisol. 48 adults with uncontrolled hypertension took baxdrostat or a placebo for 8 weeks. Researchers measured cortisol levels before and after a stimulation test to see if the drug causes any adrenal problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
baxdrostat
What this could lead to
If successful, this study could help understand whether baxdrostat is safe for the adrenal glands in people with high blood pressure.
What could go wrong
This is a small, early-phase study focused on a safety marker, not on treating hypertension. The results may not apply to larger populations or show any clinical benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

48 people

The number who actually took part.

Started

Jun 2024

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with mean seated systolic blood pressure (SBP) on automated office blood pressure measurement (AOBPM) greater than equal to (\>=) 130 millimeter of mercury (mmHg) and less than (\<) 170 mmHg at screening. * Participants with mean seated SBP on AOBPM of \>=130 mmHg and \< 170 mmHg at randomization. * Participants must have a stable regimen of \>=1 antihypertensive medication (at least one should be a diuretic), for at least 4 weeks prior to screening. * Participants must have an estimated glomerular filtration rate (eGFR) \>=45 milliliter per minute (mL/min)/1.73-meter square (m\^²) at screening. * Participants must have a serum potassium+ (K+) level \>=3.5 and \< 5.0 millimole per liter (mmol/L) at screening. Exclusion Criteria: * Mean seated diastolic blood pressure (DBP) on AOBPM \>=110 mmHg at randomization. * Prior treatment (within the 4 weeks before screening) with angiotensin receptor Blocker (ARBs) and angiotensin converting enzyme inhibitor (ACEIs) (both taken simultaneously). * Serum sodium (Na+) level \< 135 millimole per liter (mmol/L) at screening, determined as per central laboratory. * New York heart association functional heart failure (HF) Class IV at screening. * Planned percutaneous coronary intervention/coronary artery bypass grafting or percutaneous coronary intervention/coronary artery bypass grafting done within 6 months prior to screening. * Uncontrolled diabetes with glycated haemoglobin (HbA1c) \> 10.0% (86 mmol/mol) at screening. * Fridericia's corrected QT (QTcF) value \> 470 milliseconds (ms) at screening, unless having a pacemaker. * Heart rate \< 45 or \> 110 beats/min in a resting position, as per vital signs assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Uncontrolled hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Uncontrolled hypertension

Contacts and locations

Locations

  • Research Site

    Phoenix, Arizona, 85018, United States

  • Research Site

    Tempe, Arizona, 85281, United States

  • Research Site

    Montclair, California, 91763, United States

  • Research Site

    Tarzana, California, 91356, United States

  • Research Site

    Tampa, Florida, 33612, United States

  • Research Site

    Chicago, Illinois, 60643, United States

  • Research Site

    Metairie, Louisiana, 70006, United States

  • Research Site

    Houston, Texas, 77074, United States

  • Research Site

    Houston, Texas, 77099, United States

  • Research Site

    Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.